PDCD1 and B-cell chronic lymphocytic leukemia: This is the case, for example, of the PD-1 blocking antibodies that did not show any evidence of clinical response or benefit in CLL trials, neither as single agents nor in combination with ibrutinib, unless patients underwent Richter’s transformation [137,138].